Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Abstract Background Autologous stem cell transplantation (ASCT) has been recommended as a standard approach for young multiple myeloma (MM) patients for decades, even in the era of novel agents. Gain of chromosome 1q21 is a common cytogenetic abnormality in MM, while its clinical prognostic value is...
Main Authors: | Wen Gao, Yuan Jian, Juan Du, Xiaozhe Li, Huixing Zhou, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Weijun Fu, Juan Li, Wenming Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-11-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3254 |
Similar Items
-
What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
by: Wen Gao, et al.
Published: (2020-10-01) -
UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-01-01) -
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
by: Patrizia Tosi
Published: (2014-07-01) -
UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-11-01) -
Double Autologous Stem Cell Transplantation in a Case of Non-secretory Multiple Myeloma
by: Lázár Erzsébet, et al.
Published: (2016-12-01)